Cerus Corporation (CERS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cerus Corporation (CERS) Healthcare & Pipeline Overview

Cerus Corporation develops and commercializes the INTERCEPT Blood System, a proprietary technology designed to enhance blood safety by reducing blood-borne pathogens in donated blood components intended for transfusion, serving hospitals and blood banks across the United States, Europe, and other international markets.

What Is the Investment Thesis for CERS?

Cerus Corporation's investment thesis centers on the increasing global demand for safer blood transfusion practices. The INTERCEPT Blood System's ability to inactivate a broad spectrum of blood-borne pathogens represents a significant value proposition for hospitals and blood banks. Key value drivers include the expansion of INTERCEPT's adoption in existing markets, particularly in Europe and the United States, and regulatory approvals in new geographies. The company's gross margin of 54.3% indicates a strong pricing power. Upcoming catalysts include potential new contracts with large hospital networks and expanded regulatory approvals for red blood cell applications. However, investors should be aware of potential risks such as competition from alternative blood safety technologies and the need for continued innovation to maintain market leadership. The company's current market capitalization is $0.39 billion.

Based on FMP financials and quantitative analysis

CERS Key Highlights

Cerus Corporation operates in the medical device industry, focusing on blood safety.

• The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components.
• The company's gross margin stands at 54.3%, indicating strong pricing power.
• Cerus sells its products through a direct sales force and distributors across the United States, Europe, and other international markets.
• Cerus Corporation's market capitalization is $0.39 billion as of 2026-05-10.

Who Are CERS's Competitors?

CERS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CERS's Key Strengths?

Proprietary INTERCEPT Blood System technology.

• Regulatory approvals in key markets.
• Established relationships with hospitals and blood banks.
• Direct sales force and distribution network.

What Are CERS's Weaknesses?

Limited product portfolio focused primarily on blood safety.

• Dependence on regulatory approvals for new applications.
• Negative profit margin of -4.3%.
• Relatively small market capitalization of $562M.

What Could Drive CERS Stock Higher?

Potential new contracts with large hospital networks.

• Expanded regulatory approvals for red blood cell applications.
• Increasing adoption of INTERCEPT Blood System in existing markets.
• Expansion of sales and marketing efforts in key regions.

What Are the Key Risks for CERS?

Financial-distress signal — its Altman Z-Score of -3.33 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-15.4%) — the business is not currently generating profit on shareholder capital.
• Competition from alternative blood safety technologies.
• Changes in regulatory requirements.
• Economic downturn affecting hospital budgets.
• Dependence on regulatory approvals for new applications.

What Are the Growth Opportunities for CERS?

• Expansion in European Markets: Cerus has a significant opportunity to expand its market share in Europe, where the INTERCEPT Blood System is already approved. Focused sales and marketing efforts targeting key European countries, such as Germany and France, could drive increased adoption. The European blood transfusion market is substantial, with a potential market size estimated at $1 billion annually. This expansion could be realized within the next 3-5 years through strategic partnerships and regulatory advancements.
• U.S. Market Penetration: Increasing penetration in the U.S. market represents a substantial growth opportunity for Cerus. By securing contracts with major hospital networks and blood centers, Cerus can significantly increase its revenue. The U.S. blood transfusion market is one of the largest globally, with an estimated value of over $5 billion. Achieving a 10% market share in the U.S. within the next 5 years is a realistic goal, driven by growing awareness of the benefits of pathogen inactivation.
• Red Blood Cell Application: The INTERCEPT Blood System for red blood cells represents a significant growth avenue. Regulatory approvals in key markets, such as the U.S. and Europe, would unlock a substantial market opportunity. The market for pathogen-reduced red blood cells is estimated at $2 billion globally. Securing these approvals within the next 3 years could position Cerus as a leader in red blood cell safety.
• Emerging Markets: Expanding into emerging markets, such as Latin America and Asia, offers long-term growth potential. These regions often have less stringent regulatory environments and a growing demand for safer blood transfusion practices. The combined market size of these regions is estimated at $1.5 billion. Establishing distribution networks and securing initial regulatory approvals within the next 5-7 years could provide a significant boost to Cerus's revenue.
• Cryoprecipitation Market: The INTERCEPT Blood System for Cryoprecipitation presents a niche but valuable growth opportunity. By targeting hospitals and blood centers that require pathogen-reduced cryoprecipitated fibrinogen complex, Cerus can expand its product portfolio and revenue streams. The global market for cryoprecipitation products is estimated at $500 million. Capturing a 20% market share within the next 3-5 years is achievable through targeted marketing and product development efforts.

What Are CERS's Competitive Advantages?

• Proprietary INTERCEPT Blood System technology.
• Regulatory approvals in key markets.
• Established relationships with hospitals and blood banks.
• Direct sales force and distribution network.

What Does CERS Do?

Cerus Corporation, incorporated in 1991 and headquartered in Concord, California, is a biomedical products company focused on enhancing blood safety. The company's core offering is the INTERCEPT Blood System, a technology designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. This system targets pathogens in platelets, plasma, and red blood cells, aiming to reduce the risk of transfusion-transmitted infections. Cerus sells its INTERCEPT Blood Systems for platelets and plasma, designed to inactivate pathogens in these blood components. They also offer the INTERCEPT Blood System for red blood cells, which inactivates pathogens in red blood cells. Additionally, the INTERCEPT Blood System for Cryoprecipitation utilizes the plasma system to produce pathogen-reduced cryoprecipitated fibrinogen complex, used in treating and controlling bleeding associated with fibrinogen deficiency. Cerus markets and sells these systems through a direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international regions. The company's focus on innovation in blood safety positions it within the medical device industry, catering to hospitals and blood banks seeking to enhance the safety and quality of blood transfusions.

What Products and Services Does CERS Offer?

• Develops and commercializes the INTERCEPT Blood System.
• Offers solutions for pathogen inactivation in platelets, plasma, and red blood cells.
• Provides systems for pathogen-reduced cryoprecipitated fibrinogen complex.
• Sells products through a direct sales force and distributors.
• Enhances blood safety by reducing blood-borne pathogens in transfusions.
• Caters to hospitals and blood banks seeking safer blood transfusion practices.

How Does CERS Make Money?

• Sells INTERCEPT Blood Systems to hospitals and blood banks.
• Generates revenue through direct sales and distribution agreements.
• Focuses on pathogen inactivation in blood components.
• Provides solutions for platelets, plasma, red blood cells, and cryoprecipitation.

What Industry Does CERS Operate In?

Cerus Corporation operates within the medical device industry, specifically focusing on blood safety. The market for blood transfusion safety is driven by increasing awareness of transfusion-transmitted infections and stringent regulatory requirements. The industry is characterized by a competitive landscape with companies offering various pathogen reduction technologies. Cerus's INTERCEPT Blood System competes with other methods for ensuring blood safety, such as bacterial detection and pathogen filtration. The global blood transfusion market is expected to grow, driven by aging populations and increasing surgical procedures, creating opportunities for Cerus to expand its market share.

Who Are CERS's Key Customers?

• Hospitals
• Blood banks
• Transfusion centers
• Healthcare providers

Cerus Corporation (CERS) Valuation Context

Valued at $562M, CERS is classified as a small-cap stock. Relative to its peer group, CERS's quantitative score of 17/100 is below the peer average of 75/100.

CERS Revenue & Earnings Trend

In Q2 2026, CERS generated $57.4M in top-line revenue, marking a sequential increase of 7.0%. The company recorded a net loss of $2.9M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CERS averaged $-0.01 in diluted EPS.

Company Profile

Cerus Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Concord, US. The company is led by CEO Vivek K. Jayaraman. CERS has traded publicly since 1997.

Return on equity for Cerus Corporation stands at -15.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

Cerus Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.33 places it in the distress zone, a signal of elevated financial risk.

Cerus Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 16.0% above estimates on average.

Wall Street analysts project Cerus Corporation revenue of about $253.7M for fiscal 2026, with EPS near $-0.04.

CERS Financials

CERS Latest News

CERS Analyst Consensus

CERS MoonshotScore

Cerus Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources